Fact Check: Two IP-Related Bills Would Harm U.S. Innovation, Not Help It
Congress is considering several ill-conceived bills that purport to address abuses in the patent system, but would in reality weaken core intellectual property protections, undermine U.S. innovation leadership, and benefit foreign competitors at America’s expense. Last month, we examined the flaws behind two of them: the Drug Competition Enhancement Act and the Affordable Prescriptions for